Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 673,000 | 560,000 | 434,000 | 363,329 | 351,406 |
| Cost of Goods | 109,000 | 77,000 | 45,000 | 28,320 | 16,008 |
| Gross Profit | 564,000 | 483,000 | 389,000 | 335,009 | 335,398 |
| Operating Expenses | 1,099,000 | 1,019,000 | 958,000 | 984,248 | 717,143 |
| Operating Income | -535,000 | -536,000 | -569,000 | -648,919 | -381,737 |
| Interest Expense | 62,000 | 63,000 | 66,000 | 43,015 | 29,422 |
| Other Income | 26,000 | 32,000 | 26,000 | -9,791 | -41,822 |
| Pre-tax Income | -571,000 | -567,000 | -609,000 | -701,725 | -452,981 |
| Income Tax | 4,000 | 2,000 | -2,000 | 5,696 | 1,044 |
| Net Income Continuous | -575,000 | -569,000 | -607,000 | -707,421 | -454,025 |
| Net Income | $-575,000 | $-569,000 | $-607,000 | $-707,421 | $-454,025 |
| EPS Basic Total Ops | -5.83 | -6.29 | -8.25 | -10.12 | -6.70 |
| EPS Basic Continuous Ops | -5.83 | -6.29 | -8.26 | -10.12 | -6.70 |
| EPS Diluted Total Ops | -5.83 | -6.29 | -8.25 | -10.12 | -6.70 |
| EPS Diluted Continuous Ops | -5.83 | -6.29 | -8.26 | -10.12 | -6.70 |
| EPS Diluted Before Non-Recurring Items | -5.83 | -6.29 | -8.25 | -9.05 | -6.34 |
| EBITDA(a) | $-504,000 | $-513,000 | $-556,000 | $-628,000 | $-361,892 |